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expressed recombinant EDIII protein is antigenically active
and potentially useful for detecting antibodies against yel-
low fever virus.
doi:10.1016/j.ijid.2010.02.159314th International Congress on Infectious Diseases (ICID) Abs
experiments showed that mAb 2A10G6 protected sucking
mice from lethal dengue 1-4 viruses challenge in a dose-
dependent manner. Thus, we have established a novel
ﬂavivirus cross-reactive neutralizing mAb 2A10G6. Phage-
displayed random peptide library mapped the epitope of
mAb 2A10G6 to a common antigenic site within the highly
conserved N-terminal fusion loop peptide of ﬂavivirus enve-
lope protein. Functional assays conﬁrmed that mAb 2A10G6
bind with the fusion peptide and blocks infection primarily
at a step after viral attachment.
Conclusion: Together, these experiments deﬁne the char-
acteristics of a novel ﬂavivirus cross-reactive neutralizing
MAb 2A10G6 and make it a suitable candidate for human-
ization into a therapeutic antibody to treat severe ﬂavivirus
infections in human.
doi:10.1016/j.ijid.2010.02.1591
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Background: Crimean-Congo haemorrhagic fever (CCHF)
virus causes a severe and often fatal infection. The virus has
the propensity to cause nosocomial infections and hence a
rapid and sensitive diagnosis is important for isolation of the
patient for protection of health care workers and implemen-
tation of supportive therapy. Current serological diagnostic
assays are based on enzyme linked immunosorbent assays
(ELISA) or immunoﬂuorescence (IF) tests using inactivated
virus which necessitates biosafety level (BSL) 4 facilities for
preparation of reagents. The aim of the study was to pre-
pare a safe recombinant nucleoprotein (NP) and determine
its suitability for detection of antibody responses in survivors
of CCHF infection. To facilitate protein expression the gene
encoding the nucleoprotein was optimized for E.coli usage.
Methods: The CCHF nucleoprotein gene coding sequence
was submitted to GenScript (USA). OptimumGene software
was used to optimize codon usage, GC content, elimi-
nate polyadenylation sites and modify cis-acting sites. The
optimized gene was synthesized and the nucleoprotein
expressed in an E.coli bacterial expression system with
a His tag for puriﬁcation. CCHF antibody positive human
sera were tested in an ELISA using the recombinant NP
antigen.
Results: A direct ELISA was developed in which plates
were coated with the recombinant NP antigen and reacted
with convalescent human sera from conﬁrmed CCHF
patients. The antigen expressed from the optimized NP gene
was found to detect IgG antibodies against CCHF virus.
Conclusion: Recombinant proteins have been shown to
be safe, cost effective reagents that can be prepared for
biohazardous pathogens without the requirements of BSL
4 facilities. Optimization of the CCHF N gene was essen-
tial for high expression of soluble NP. The protein expressed
was shown to react against antibodies in convalescent CCHF
patients. A panel of serum samples from conﬁrmed patientsts e47
ill be used to determine the speciﬁcity and sensitivity of
he ELISA for diagnostic purposes.
oi:10.1016/j.ijid.2010.02.1592
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Background: Yellow fever virus belongs to the genus Fla-
ivirus, of the family Flaviviridae. It is a mosquito-borne
irus endemic in tropical regions of Africa and South Amer-
ca. Although an effective vaccine is available, the virus
emains a major public health threat, particularly in Africa
here vaccination is limited by poverty, civil wars and the
naccessibility of rural areas prone to outbreaks. It is a re-
merging pathogen with case-fatality rates that can exceed
0%. The diagnosis of infection and testing of the immune
tatus of vaccinees require reagents that are prepared in
iosafety level 3 and 4 facilities. The viral envelope pro-
ein plays an important role in eliciting antibodies and hence
erves as an ideal diagnostic and research tool for the detec-
ion of antibodies. The aim of the study was to compare
arious bacterial expression systems for the preparation of
recombinant yellow fever viral envelope protein for the
etection of antibodies against yellow fever in vaccinated
ndividuals.
Methods: The domain III region of the envelope (EDIII)
ene was ampliﬁed with primers identiﬁed using sequence
ata retrieved from GenBank. The EDIII gene was cloned
nto three different E.coli bacterial expression systems for
omparison of protein yield, solubility and suitablity in an
LISA. Proteins were all expressed with an N+ terminal His
ag for puriﬁcation. A direct ELISA was developed in which
he plates were coated with antigen and reacted with serum
amples from vaccinees.
Results: Each antigen was evaluated using serum samples
ollected from vaccinees and serological cross reactivity
f the antigen against heterologous ﬂaviviral antibody was
etermined using convalescent serum samples from patients
ith known ﬂaviviral infections, such as West Nile. Protein
ields varied signiﬁcantly between the different expression
ystems with higher yields and increased solubility obtained
rom expression at lower temperatures. Higher reactivity
as associated with homologous antibody.
Conclusion: Preliminary results suggest that bacterially
